Healthcare

HealthEquity runs a scaled platform for HSAs and other healthcare spending accounts, combining recurring service fees with custodial and payment revenue. Margins and cash flow have improved sharply, making its niche position more compelling to examine in depth.

Heartflow develops AI-based heart imaging analysis that helps doctors assess coronary artery disease without invasive testing. Rapid revenue growth, expanding clinical use, and a focused position in cardiac CT make it a company worth a closer look.

Hims & Hers is building a scaled digital healthcare platform around telehealth, subscriptions, and prescription fulfillment. Rapid revenue expansion, rising cash generation, and growing weight-management exposure make its long-term market position worth a closer look.

Haemonetics develops blood and plasma collection and hospital technologies, with plasma now the main growth engine. Rising cash flow, specialized market positions, and recurring disposables make the business worth a closer look despite a more demanding valuation.

Hikma Pharmaceuticals makes generic, injectable, and branded medicines across the U.S., Europe, and MENA. Its appeal comes from strong profitability, resilient cash generation, and a valuable niche in complex injectables, while the market still applies a cautious valuation.

GRAIL develops Galleri, a blood test designed to detect many cancers early from a single draw. The appeal lies in a very large screening opportunity, fast revenue growth, and a low-debt balance sheet, while the long-term outcome depends on scaling adoption into mainstream care.

Erasca is a precision-oncology biotech focused on RAS-driven cancers, a major area of unmet need. Its appeal rests on a concentrated pipeline, improving cash-burn trend, and a stronger funding base that gives its clinical programs time to prove their value.